Effect of the Janus kinase inhibitor tofacitinib in the treatment of juvenile scleroderma: A single-center experience

被引：0
|
作者：
Colussi, Lara [1 ]
Dagri, Arianna [2 ]
Pastore, Serena [3 ]
Tommasini, Alberto [1 ,3 ]
Pin, Alessia [3 ]
Taddio, Andrea [1 ,3 ]
机构：
[1] Univ Trieste, Dept Med Surg & Hlth Sci, Trieste, Italy
[2] Univ Udine, Dept Med DAME, Div Pediat, Udine, Italy
[3] Inst Maternal & Child Hlth IRCCS Burlo Garofolo, Trieste, Italy
来源：
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES | 2024年 / 27卷 / 08期
关键词：
LOCALIZED SCLERODERMA;
D O I：
10.1111/1756-185X.15295
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] The Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Tofacitinib, an Orally Active Janus Kinase Inhibitor
    Lawendy, Nervin
    Lamba, Manisha
    Chan, Gary
    Wang, Rong
    Alvey, Christine W.
    Krishnaswami, Sriram
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2014, 3 (06): : 421 - 427
  • [32] Treatment of hepatocellular carcinoma: A single-center experience
    Florio, F
    Nardella, M
    Balzano, S
    Caturelli, E
    Siena, D
    Cammisa, M
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 1997, 20 (01) : 23 - 28
  • [33] The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Tofacitinib, a Janus Kinase Inhibitor, in Humans
    Dowty, Martin E.
    Lin, Jinyan
    Ryder, Tim F.
    Wang, Weiwei
    Walker, Gregory S.
    Vaz, Alfin
    Chan, Gary L.
    Krishnaswami, Sriram
    Prakash, Chandra
    DRUG METABOLISM AND DISPOSITION, 2014, 42 (04) : 759 - 773
  • [34] Treatment of hepatocellular carcinoma: A single-center experience
    Francesco Florio
    Michele Nardella
    Silverio Balzano
    Eugenio Caturelli
    Domenico Siena
    Mario Cammisa
    CardioVascular and Interventional Radiology, 1997, 20 : 23 - 28
  • [35] Tofacitinib in treatment-experienced patients with ulcerative colitis: A single-center real-world experience in Australia
    Lo, S. W.
    Connell, W.
    Kamm, M. A.
    Lust, M.
    Wright, E. K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 122 - 123
  • [36] Antipruritic Effects of Janus Kinase Inhibitor Tofacitinib in a Mouse Model of Psoriasis
    Hashimoto, Takashi
    Sakai, Kent
    Sanders, Kristen M.
    Yosipovitch, Gil
    Akiyama, Tasuku
    ACTA DERMATO-VENEREOLOGICA, 2019, 99 (03) : 298 - 303
  • [37] Effects of Diabetes Mellitus on the Disposition of Tofacitinib, a Janus Kinase Inhibitor, in Rats
    Gwak, Eun Hye
    Yoo, Hee Young
    Kim, So Hee
    BIOMOLECULES & THERAPEUTICS, 2020, 28 (04) : 361 - 369
  • [38] Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis
    Dowty, Martin E.
    Jesson, Michael I.
    Ghosh, Sarbani
    Lee, Jamie
    Meyer, Debra M.
    Krishnaswami, Sriram
    Kishore, Nandini
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2014, 348 (01): : 165 - 173
  • [39] SGLT-2 Inhibitor Treatment in Renal Transplant Recipients: A Single-Center Experience
    Liriano-Ward, Luz E.
    Stefan, Simona
    Campbell, Alesa
    Al Azzi, Yorg
    Ajaimy, Maria
    Pynadath, Cindy T.
    Campos, Pablo Loarte
    Akalin, Enver
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 650 - 650
  • [40] Glucocorticoid sparing in sarcoidosis using the Janus kinase (JAK) inhibitor tofacitinib
    Belliere, Julie
    Laurent, Camille
    Noel-Savina, Elise
    Pugnet, Gregory
    Faguer, Stanislas
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2022, 98 : 119 - 121
12345